{"id":"NCT00641537","sponsor":"EMD Serono Research & Development Institute, Inc.","briefTitle":"CLARITY Extension Study","officialTitle":"A Phase IIIb, Double-Blind, Placebo-Controlled, Multicenter, Parallel Group, Extension Trial to Evaluate the Safety and Tolerability of Oral Cladribine in Subjects With Relapsing-Remitting Multiple Sclerosis Who Have Completed Trial 25643 (CLARITY)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-02-29","primaryCompletion":"2011-12-31","completion":"2011-12-31","firstPosted":"2008-03-24","resultsPosted":"2013-12-02","lastUpdate":"2020-12-07"},"enrollment":867,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Relapsing-Remitting Multiple Sclerosis"],"interventions":[{"type":"DRUG","name":"Cladribine","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Cladribine","otherNames":[]},{"type":"DRUG","name":"Cladribine","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Cladribine Low/Placebo (LLPP)","type":"PLACEBO_COMPARATOR"},{"label":"Cladribine High Dose/Placebo (HLPP)","type":"PLACEBO_COMPARATOR"},{"label":"Cladribine Low/Low Dose (LLLL)","type":"EXPERIMENTAL"},{"label":"Cladribine High/Low Dose (HLLL)","type":"EXPERIMENTAL"},{"label":"Placebo/Cladribine Low Dose (PPLL)","type":"EXPERIMENTAL"},{"label":"Placebo/No Treatment","type":"NO_INTERVENTION"},{"label":"Cladribine 3.5 mg/kg/No Treatment","type":"NO_INTERVENTION"},{"label":"Cladribine 5.25 mg/kg/No Treatment","type":"NO_INTERVENTION"}],"summary":"The purpose of this extension trial was to further evaluate the safety and tolerability of oral cladribine in subjects who have previously completed treatment within Trial 25643 (CLARITY). This trial also explored clinical benefit of prolonged 192-week versus 96-week treatment.","primaryOutcome":{"measure":"Safety Population: Percentage of Participants With at Least 1 Common Terminology Criteria for Adverse Events Version 3.0 (CTCAE) Grade 4 Hematologic and Hepatic Toxicity","timeFrame":"Baseline up to Week 120","effectByArm":[{"arm":"Cladribine Low/Placebo (LLPP)","deltaMin":0,"sd":null},{"arm":"Cladribine High Dose/Placebo (HLPP)","deltaMin":0,"sd":null},{"arm":"Cladribine Low/Low Dose (LLLL)","deltaMin":2.7,"sd":null},{"arm":"Cladribine High/Low Dose (HLLL)","deltaMin":3.2,"sd":null},{"arm":"Placebo/Cladribine Low Dose (PPLL)","deltaMin":0.4,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":null},"locations":{"siteCount":116,"countries":["United States","Australia","Austria","Belgium","Brazil","Bulgaria","Canada","Croatia","Czechia","Denmark","Estonia","Finland","France","Germany","Greece","Italy","Latvia","Lebanon","Lithuania","Morocco","Netherlands","Poland","Portugal","Russia","Saudi Arabia","Serbia","Switzerland","Tunisia","Turkey (TÃ¼rkiye)","Ukraine","United Kingdom"]},"refs":{"pmids":["36017797","36017780","35003076","34370275","33969750","32447743","29399054"],"seeAlso":["https://clinicaltrials.emdgroup.com/en/trial-details/?id=27820","https://medical.emdserono.com/en_US/home.html"]},"adverseEventsSummary":{"seriousAny":{"events":16,"n":98},"commonTop":["Lymphopenia","Nasopharyngitis","Headache","Back pain","Influenza"]}}